GlaxoSmithKline update on FDA review of Cervarix
GlaxoSmithKline (NYSE: GSK) announced today the U.S. Food and Drug Administration (FDA) has not yet completed the review of the Biologics License Application (BLA) for CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant], the Company’s candidate cervical cancer vaccine. As a result of this, the review will continue beyond the September 29, 2009, action date
Issued: Tuesday 29 September 2009
GlaxoSmithKline (NYSE: GSK) announced today the U.S. Food and Drug Administration (FDA) has not yet completed the review of the Biologics License Application (BLA) for CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant], the Company’s candidate cervical cancer vaccine. As a result of this, the review will continue beyond the September 29, 2009, action date.
GSK remains confident in the BLA submission and expects the FDA to complete their review soon.
The BLA was submitted to the FDA in March 2009.
GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Enquiries: |
||
|
UK Media enquiries: |
Philip Thomson |
(020) 8047 5502 |
|
|
Claire Brough |
(020) 8047 5502 |
|
|
Stephen Rea |
(020) 8047 5502 |
|
|
Gwenan White |
(020) 8047 5502 |
|
|
|
|
|
US Media enquiries: |
Nancy Pekarek |
(919) 483 2839 |
|
|
Mary Anne Rhyne |
(919) 483 2839 |
|
|
Kevin Colgan |
(919) 483 2839 |
|
|
Lisa Behrens |
(919) 483 2839 |
|
|
||
|
European Analyst/Investor enquiries: |
David Mawdsley |
(020) 8047 5564 |
|
Sally Ferguson |
(020) 8047 5543 |
|
|
Gary Davies |
(020) 8047 5503 |
|
|
US Analyst/ Investor enquiries: |
Tom Curry |
(215) 751 5419 |
|
Jen Hill Baxter |
(215) 751 7002 |
